AngioDynamics is an International Company with facilities in Europe, Asia and North America. Originally founded in Queensbury, N.Y., U.S., in 1988, AngioDynamics’ is best characterized by innovation and growth. Today, the Company’s global reach goes far beyond “Catheter Valley,” an area in New York's state named for its long history of catheter and other medical device manufacturing. With 1,400 employees worldwide, AngioDynamics is currently selling in more than 50 markets through direct sales and distributors. Initially dedicated to the research and development of products used in interventional radiology, AngioDynamics began shipping product in the early 1990s. The Company soon became well established as a producer of diagnostic catheters for non-coronary angiogram and thrombolytic delivery systems. In May 2004 the Company became publicly traded on the NASDAQ stock exchange under the symbol ANGO.


Through acquisitions of companies such as RITA Medical Systems in January 2007, Oncobionic in May 2008, and the assets of Diomed in June 2008 and FlowMedica in January 2009, AngioDynamics now boasts a diverse product line that includes market-leading radiofrequency ablation and NanoKnife systems, NAMIC fluid management systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, venous products and targeted renal therapy products. Continuing its expansion, AngioDynamics opened a new headquarters in Albany, N.Y., in March 2010. Most recently, in May 2012, AngioDynamics acquired Navilyst Medical, bringing market-leading fluid management systems into its portfolio. The acquisition significantly expanded the Company's scale, doubling its share of the vascular access market while building critical mass in the peripheral vascular market.

1988 - Company is founded as a division of E-Z-EM Inc. dedicated to the research and development of products used in interventional radiology.


Early 1990s - Product shipments begin, and the company soon becomes well established as a producer of diagnostic catheters for non-coronary angiography and thrombolytic delivery systems.


1992 - The company is organized in the state of Delaware under the name A.D. Inc. and as a wholly owned subsidiary of E-Z-EM.


1996 - Name officially changes to AngioDynamics Inc. after E-Z-EM transfers its A.D. division to the subsidiary.


June 1996 - Eamonn P. Hobbs becomes president and chief executive officer of AngioDynamics.


May 2004 - AngioDynamics becomes publically traded on the NASDAQ stock exchange as ANGO.


June 2004 - AngioDynamics completes its initial public offering of shares of common stock. After the offering, E-Z-EM holds 80.4 percent of company shares.


October 2004 - E-Z-EM distributes its shares of AngioDynamics common stock to its stockholders, completed the spinoff of AngioDynamics.


June 2005 - AngioDynamics common stock is added to the Russell 3000 index and the new Russell Microcap Index following Russell Investment Group's reconstitution of its family of U.S. indices.


July 2005 - AngioDynamics is chosen to be a founding member of the new NASDAQ Health Care Index sm.


November 2005 - Sotradecol is launched at the 19th Annual Congress of the American College of Phlebology meeting. AngioDynamics has an agreement with Bioniche Pharma Group Limited to distribute Sotradecol, sodium tetradecyl sulfate, for the treatment of small, uncomplicated varicose veins. The agreement gives AngioDynamics exclusive rights to market and distribute Sotradecol to interventional radiologists, vascular surgeons, cardiologists and general surgeons in the U.S. Sotradecol is the only FDA-approved, sodium tetradecyl sulfate injection in the U.S.


December 2005 - TOTAL ABSCESSION - a general drainage catheter designed to percutaneously drain abscesses and other fluid collections - is launched. It features a tamper-resistant locking mechanism known as the VAULT. This unique feature eliminates additional procedures to replace drainage catheters when the locking pigtail shape becomes unlocked during routine catheter maintenance. The VAULT reduces physician time and increases patient comfort.


April 2006 - AngioDynamics is named to Business Week's list of 100 Hot Growth Companies.


May 2006 - The Morpheus CT PICC Insertion Kit is launched nationwide. Use of the insertion kit allows the AngioDynamics proprietary peripherally inserted central catheter (PICC) to be inserted at a patient's bedside, instead of in the interventional radiology suite at the hospital, which is the current practice.


May 2006 - The follow-on public offering of AngioDynamics shares of common stock is completed.


July 2006 - AngioDynamics amends its agreement with Bioniche Pharma Group Limited to expand its market to be the sole distributor of Sotradecol in all markets in the United States.


September 2006 - AngioDynamics announces a facility expansion at the company's Queensbury, N.Y., U.S., headquarters, consisting of a 36,000-square-foot warehouse and distribution center to accommodate its increasing number of employees and provide a foundation for future growth of the organization.


October 2006 - AngioDynamics is recognized as No. 11 on the Forbes 200 Best Small Companies in America list.


November 2006 - AngioDynamics announces the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Oncobionic Inc. to market irreversible electroporation (IRE) - a technology indicated for surgical ablation of soft tissue.


November 2006 - AngioDynamics and RITA Medical System Inc. - a respected provider of medical oncology devices - announce the signing of a definitive agreement whereby AngioDynamics will acquire RITA.


January 2007 - AngioDynamics completes the acquisition of RITA Medical Systems. The acquisition includes facilities in California and Georgia, increases the company's total number of employees from around 200 to nearly 550 and gives AngioDynamics immediate access to the burgeoning interventional oncology market through RITA's specialized sales force.


February 2007 - AngioDynamics introduces the Smart Port CT at the 32nd Annual Scientific Meeting of the Society of Interventional Radiology. The new, vascular access port is indicated for power injection of contrast media with a flow rate of 5mL/sec.


May 2007 - AngioDynamics introduces the Profiler Balloon Dilatation Catheter in the U.S. market. The new, low-profile balloon catheter is indicated for general percutaneous transluminal angioplasty (PTA) of the iliac, femoral and renal arteries, and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.


August 2007 - Vincent Bucci is elected chairman of the AngioDynamics Board of Directors. Mr. Bucci joined the AngioDynamics Board in January 2007 when AngioDynamics acquired RITA Medical Systems; he had been Chairman of the RITA Medical Systems Board since 2003 and a Board member since 1994.


January 2008 - Centros - a self-centering, tunneled hemodialysis access catheter - is launched.


February 2008 - AngioDynamics employees celebrate the company's 20th Anniversary by ringing the closing bell at the NASDAQ stock exchange.


April 2008 - Irreversible electroporation (IRE) technology is successfully used in the first human clinical trial for the treatment of soft tissue.


April 2008 - AngioDynamics announces it has entered into an asset purchase agreements with Diomed Holdings Inc., Diomed Inc. and Diomed Limited for the acquisition of certain assets of Diomed's business in the United States and United Kingdom.


May 2008 - Following the successful initial use of Oncobionic's IRE technology, AngioDynamics completes the acquisition of Oncobionic Inc. per the terms of the Oct. 12, 2006, agreement


June 2008 - The acquisition of certain U.S. and U.K. assets of Diomed Ltd. is completed, substantially strengthening the AngioDynamics' position in the market for the treatment of varicose veins.


June 2008 - AngioDynamics reorganizes into three business units - Peripheral Vascular, Access and Oncology/Surgery - to better serve its customers.


November 2008 - A new varicose vein therapy brand, VenaCure EVLT, is launched at the American College of Phlebology (ACP) 22nd Annual Congress. The new brand encompasses the best of AngioDynamics' VenaCure product line as well as EVLT, a product line which AngioDynamics recently rescued from the bankruptcy of Diomed Inc.


November 2008 - The first percutaneous uses of IRE technology on liver and kidney lesions were conducted at The Alfred in Melbourne, Australia. Using AngioDynamics' NanoKnife system, Dr. Ken Thomson, Professor and Director of the Department of Radiology at The Alfred, Monash University, performed a kidney case and two liver cases.


December 2008 - AngioDynamics announces the implementation of a leadership development plan combining succession planning with senior management team expansion. President and CEO Eamonn P. Hobbs announces he will be stepping down when a successor is identified.


January 2009 - Jan Keltjens, an executive with more than 20 years of successful medical industry leadership experience, is appointed President and CEO of AngioDynamics.


July 2009 - The StarBurst XLi-Enhanced Semi-Flex probe is the first radiofrequency ablation (RFA) device specifically designed to deliver a 7cm ablation of a tumor in a single placement during Computed Tomography-aided procedures.


September 2009 - AngioDynamics introduces the DuraMax stepped chronic dialysis catheter at the 2009 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Scientific Meeting, held in Lisbon, Portugal. The new catheter employs Curved Tip Catheter Technology that is designed to provide higher blood flow and lower recirculation, even if the catheter becomes positioned against a blood vessel wall. This design approach eliminates the need for side holes common in other catheters, reducing the potential for clots.


September 2011 - Joseph M. DeVivo is appointed President and Chief Executive Officer of AngioDynamics, bringing with him the track record and leadership expertise. Prior to joining the ompany, Mr. DeVivo served as Global President of Smith & Nephew Orthopedics (LSE: SN, NYSE: SNN) and previously served as President and Chief Executive Officer of RITA Medical Systems.


January 2012 - AngioDynamics enters into a definitive agreement to acquire privately-held Navilyst Medical,a global medical device company with particular strengths in the vascular access, interventional radiology and interventional cardiology markets. The acquisition will significantly expand AngioDynamics' scale, doubling its share of the Vascular Access market while building critical mass in the peripheral vascular market.


March 2012 - AngioDynamics announces a strategic relationship with privately-held Microsulis Medical Ltd. - a medical device company specializing in minimally invasive, microwave ablation technology for the coagulation of soft tissue and has systems in more than 80 hospitals world-wide. The Company makes a $5 million equity investment in Microsulis through the purchase of senior preferred stock, representing a 14.3% ownership position, and is granted exclusive distribution rights to market and sell the Accu2i pMTA microwave ablation system in all markets outside the United States from May 2012 through December 2013, AngioDynamics also is granted the exclusive option to purchase, at any time until September 22, 2013, substantially all of the global assets of Microsulis Medical Ltd., including the microwave ablation technology and its worldwide distribution rights.


May 2012 - The Company's shareholders approve the issuance of approximately 9.5 million shares of AngioDynamics common stock for use in the acquisition of privately-held Navilyst Medical pursuant to the terms of the definitive acquisition agreement dated January 30, 2012.


May 2012 - AngioDynamics completes its acquisition of Navilyst Medical, with the transaction valued at $355 million. The combination of the two companies is expected to double AngioDynamics share of the vascular access market, build critical mass in the peripheral vascular market and establish a strong operating platform for future growth.


October 2012 - AngioDynamics completes its acquisition of Vortex Medical Inc., a privately-held company focused on the development of innovative medical devices for venous drainage and the removal of thrombus, or blood clots, from occluded blood vessels. Vortex is currently commercializing the AngioVac venous drainage system, which includes the AngioVac Cannula and Circuit. Both the AngioVac Cannula and Circuit are FDA-cleared for use during extracorporeal bypass for up to 6 hours, and an application has been filed for CE Mark approval.


October 2013 - The Company acquired privately-held Clinical Devices, B.V., to obtain the global rights to a next-generation tip location technology currently under development. As part of the transaction, AngioDynamics will also acquire its Netherlands-based distributor of NAMIC fluid management products.